Improving the immunogenicity of E. coli FimH via multivalent display on I53-50 nanoparticles - Top-Institutions - MDSpire

Enhancing the Immunogenic Response of E. coli FimH through Multivalent Presentation on I53-50 Nanoparticles

  • By

  • Rebecca S. Cole

  • Natalie C. Silmon de Monerri

  • Jacqueline Lypowy

  • Christopher Ponce

  • Cara Kobylarz

  • Lily Liu

  • Zein Kasbo

  • Elizabeth Kepl

  • Tara Ciolino

  • Art Illenberger

  • Leslie Gallardo

  • Annalena Laporte

  • Danielle Baranova

  • Rashmi Ravichandran

  • Laurent O. Chorro

  • Robert G.K. Donald

  • Raphael Simon

  • Neil P. King

  • July 21, 2026

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    University of Washington – Institute for Protein Design
    University of Washington – Institute for Protein Design

    Seattle, Washington

    Key Differentiators

    • Immunology
    • Vaccine Development

  • #2

    Pfizer – Vaccine Research & Development
    Pfizer – Vaccine Research & Development

    Pearl River, New York

    Key Differentiators

    • Vaccine Development
    • Pharmaceutical Research

Original Source(s)

Improving the immunogenicity of E. coli FimH via multivalent display on I53-50 nanoparticles

  • by Rebecca S. Cole, Natalie C. Silmon de Monerri, Jacqueline Lypowy, Christopher Ponce, Cara Kobylarz, Lily Liu, Zein Kasbo, Elizabeth Kepl, Tara Ciolino, Art Illenberger, Leslie Gallardo, Annalena Laporte, Danielle Baranova, Rashmi Ravichandran, Laurent O. Chorro, Robert G.K. Donald, Raphael Simon, Neil P. King

  • July 21, 2026

Related Content

Nutrient deprivation increases CD3 expression in RAW cells and augments the CD3-induced proinflammatory profile, associated with NFAT and IRF-1

Patient-facing diabetic foot information from large language models: a domain- and source-balanced prompt framework for public-interface benchmarking

Can LAI-CAB Sustain Long-Term PrEP Use?

A national claims analysis found modest uptake and declining persistence over 2 years despite increasing use of injectable HIV pre-exposure prophylaxis.